ARTL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-1.570

-77.64%

-0.260

-93.98%

-0.240

-95.72%

Estimates Revision

The market is revising No Change the revenue expectations for Artelo Biosciences, Inc. (ARTL) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -67.01%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-67.01%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Artelo Biosciences Inc (ARTL.O) is -0.23, compared to its 5-year average forward P/E of -4.38. For a more detailed relative valuation and DCF analysis to assess Artelo Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.38

Current PE

-0.23

Overvalued PE

6.31

Undervalued PE

-15.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.26

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.34

Undervalued EV/EBITDA

-0.86

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ARTL News & Events

Events Timeline

No data

News

4.0

2025-11-19Benzinga

Maxim Group Lowers Artelo Biosciences Rating to Hold

9.0

2025-09-30Benzinga

Wolfspeed Shares Surge Over 50%; Check Out 20 Stocks Making Moves in Premarket Trading

8.5

2025-09-30SeekingAlpha

Artelo Biosciences Initiates Underwritten Public Offering to Secure Funding

People Also Watch

Frequently Asked Questions

What is Artelo Biosciences Inc (ARTL) stock price today?

The current price of ARTL is 1.6 USD — it has increased 3.23 % in the last trading day.

What is Artelo Biosciences Inc (ARTL)'s business?

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.

What is the price predicton of ARTL Stock?

Wall Street analysts forecast ARTL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARTL is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Artelo Biosciences Inc (ARTL)'s revenue for the last quarter?

Artelo Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Artelo Biosciences Inc (ARTL)'s earnings per share (EPS) for the last quarter?

Artelo Biosciences Inc. EPS for the last quarter amounts to -3.96 USD, increased 88.57 % YoY.

What changes have occurred in the market's expectations for Artelo Biosciences Inc (ARTL)'s fundamentals?

How many employees does Artelo Biosciences Inc (ARTL). have?

Artelo Biosciences Inc (ARTL) has 6 emplpoyees as of January 09 2026.

What is Artelo Biosciences Inc (ARTL) market cap?

Today ARTL has the market capitalization of 3.25M USD.